TSE:GEN

GeneNews (GEN) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
C$0.15
C$0.15
52-Week Range
N/A
Volume
473,147 shs
Average Volume
1.48 million shs
Market Capitalization
C$25.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GEN stock logo

About GeneNews Stock (TSE:GEN)

GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

GEN Stock News Headlines

Elon Musk Secret Crypto Plot Exposed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Elon Musk Secret Crypto Plot Exposed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Oncology Molecular Diagnostics Market by 2031
Biotech Stock Mailbag: GenVec
StageZero Life Sciences Ltd (SZLS)
See More Headlines
Receive GEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneNews and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$234,592.00
Book Value
C($0.06) per share

Miscellaneous

Free Float
N/A
Market Cap
C$25.49 million
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. James R. Howard-Tripp
    Exec. Chairman & CEO
  • Ms. Joanna M. Halsey Esq.
    Gen. Counsel, Chief Compliance Officer & HR Director of IDL
  • Prof. Choong-Chin Liew Ph.D.
    Co-Founder
  • Mr. Warren Whitehead (Age 67)
    Chief Accountant
  • Mr. David Suria
    Sr. Scientist

GEN Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of GeneNews own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GeneNews investors own include StorageVault Canada (SVI), American Airlines Group (AAL), Aareal Bank (ARL), Broadcom (AVGO), Aspen Technology (AZPN), British American Tobacco (BATS), Cronos Group (CRON) and Edwards Lifesciences (EW).

How do I buy shares of GeneNews?

Shares of GEN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:GEN) was last updated on 5/9/2024 by MarketBeat.com Staff

From Our Partners